Literature DB >> 17924969

Exploring the feasibility of selective depletion of T lymphocyte subsets by whole blood immunoadsorption cytapheresis.

M Belak1, C R Valeri, D G Wright.   

Abstract

Normal turnover of T lymphocytes is slow relative to other blood cells. Consequently, the physical removal of circulating leucocytes by thoracic duct drainage, repeated leukapheresis or blood filtration results in T cell depletion and immunosuppression. However, clinical use of such procedures is impractical compared with immunosuppressive drugs or radiation. None the less, immunosuppression by physical depletion of T cells, avoiding the systemic toxicities of drugs and radiation, might have clinical advantages if immunophenotypically distinct T cell subsets could be depleted selectively. Recent advances in targeted plasma protein apheresis using adsorbent macrobead columns prompted us to determine whether analogous techniques might permit CD4+ T lymphocytes to be removed selectively from whole blood. To explore this possibility, we linked murine anti-human-CD4 and isotype-identical control monoclonal antibodies (mAbs) to agarose, polyacrylamide and polystyrene macrobeads (150-350 microm) and then evaluated the selectivity, specificity and efficiency of macrobead columns to remove CD4+ T cells from anti-coagulated whole blood at varying mAb densities and flow rates. We also examined saturation kinetics and Fc-oriention versus random coupling of mAbs to macrobeads. Sepharose 6MB macrobead (250-350 microm) columns proved to be most effective, selectively removing up to 98% of CD4+ T cells from whole blood. Moreover, depletion efficiency and selectivity were retained when these columns were reused after elution of adherent CD4+ cells. These studies indicate that selective depletion of T lymphocyte subsets by whole blood immunoadsorption apheresis using mAb-linked macrobead columns may be feasible on a clinical scale. It is possible that such apheresis techniques could achieve targeted forms of immunosuppression not possible with drugs or radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924969      PMCID: PMC2219371          DOI: 10.1111/j.1365-2249.2007.03518.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

Review 1.  A new device for selective removal of CD4+ T cells.

Authors:  H Onodera; Y Abe; M Yoshida; N Yamawaki; Y Yamashita; H Matsuo; K Ichinose; I Otsuru; N Shibuya
Journal:  Ther Apher       Date:  1998-02

2.  Selective adsorption of human CD4 T cells.

Authors:  Hidenori Matsuo; Hirofumi Goto; Chiaki Kambara; Takayasu Fukudome; Takamitsu Mizota; Hirokazu Onodera; Makoto Yoshida; Noritoshi Shibuya
Journal:  Ther Apher Dial       Date:  2004-06       Impact factor: 1.762

Review 3.  Quo vadis haemapheresis. Current developments in haemapheresis.

Authors:  Helmut Borberg
Journal:  Transfus Apher Sci       Date:  2006-01-10       Impact factor: 1.764

Review 4.  Protein A chromatography for antibody purification.

Authors:  Sophia Hober; Karin Nord; Martin Linhult
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-10-09       Impact factor: 3.205

5.  Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.

Authors:  Jan Kurkus; Rune Nilsson; Ola Lindén; Niki Schönström; Bengt E B Sandberg; Jan Tennvall
Journal:  Artif Organs       Date:  2007-03       Impact factor: 3.094

6.  Chronic thoracic duct fistula: operative technic and physiologic effects in man.

Authors:  N L Tilney; J E Murray
Journal:  Ann Surg       Date:  1968-01       Impact factor: 12.969

7.  Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.

Authors:  T Hidaka; K Suzuki; Y Matsuki; M Takamizawa-Matsumoto; K Kataharada; T Ishizuka; M Kawakami; H Nakamura
Journal:  Arthritis Rheum       Date:  1999-03

8.  Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis.

Authors:  Y Ueki; S Yamasaki; Y Kanamoto; T Kawazu; M Yano; K Matsumoto; S Miyake; Y Tominaga; U Iwamoto; J Suemitsu; Y Matsuno; Y Sizume; Y Takenaka; K Eguchi
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

9.  Cytapheresis with a filter for selective removal of CD4+ T cells in experimental autoimmune encephalomyelitis.

Authors:  Shunya Nakane; Hidenori Matsuo; Hirofumi Goto; Megumi Yoshinaga-Matsumoto; Izumi Ohtsuru; Katsuhiro Ichinose; Hirokazu Onodera; Makoto Yoshida; Noritoshi Shibuya
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

10.  DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood.

Authors:  T Bosch; A Lennertz; B Schmidt; E Fink; C Keller; M Toepfer; J Dräger; W Samtleben
Journal:  Artif Organs       Date:  2000-02       Impact factor: 3.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.